Another promising therapy has come with UNC2025, a selective MERTK/FLT3 inhibitor that was modified from the MERTK inhibitor UNC1062 to be orally bioavailable and has activity against AML cell lines (Fig. 3).164 In preclinical studies of UNC2025, authors demonstrated that it was able to inhibit MERTK phosphorylation in BM leukemia cells, induce AML cell death, and decrease colony-forming potential and tumor cell proliferation. This evidence concerns the gene MERTK and leukemia.